Quick Takeaways
- STEMPOINT CAPITAL LP filed SCHEDULE 13G/A for Xilio Therapeutics, Inc. Common stock, par value $0.0001 per share (XLO).
- Disclosed ownership: 8.4%.
- Date of event: 31 Dec 2025.
STEMPOINT CAPITAL LP - 31 Dec 2025 SCHEDULE 13G/A Report for Xilio Therapeutics, Inc. Common stock, par value $0.0001 per share (XLO)
- Filing Manager
- STEMPOINT CAPITAL LP
- Reporting Manager
- StemPoint Capital LP
- Symbol
- XLO
- Shares outstanding
- 71,786,048 shares
- Disclosed Ownership
- 6,030,028 shares
- Ownership
- 8.4%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 10:00:09 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 14 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"STEMPOINT CAPITAL LP disclosed 8.4% ownership in Xilio Therapeutics, Inc. Common stock, par value $0.0001 per share (XLO) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 14 Nov 2025.
- Current filing was accepted on 17 Feb 2026, 10:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| StemPoint Capital LP | 8.4% | 6,030,028 | 0 | 6,030,028 | /s/ Sean C. Tan | Sean C. Tan, Authorized Signatory | |
| StemPoint Capital Management GP LLC | 8.4% | 6,030,028 | 0 | 6,030,028 | /s/ Sean C. Tan | Sean C. Tan, Authorized Signatory | |
| Michelle Ross | 8.4% | 6,030,028 | 0 | 6,030,028 | /s/ Michelle Ross | Michelle Ross |